Highlander: The Series (season 1)

Blocknative Raises $15M from Blockchain Capital, Foundry Group, and Others to Build Blocks for Ethereum

Retrieved on: 
Thursday, December 15, 2022
Ecosystem, Merge in transit, Merge, ETH, Highlander: The Series (season 1), General partnership, MEV, SAN, Professional, MetaMask, Verification and validation of computer simulation models, Cryptocurrency, Ethereum, Blockchain Capital

SAN FRANCISCO, Dec. 15, 2022 /PRNewswire-PRWeb/ -- Blocknative, the real-time web3 infrastructure company, announces a $15.0 million Series A-1 financing from Blockchain Capital, Foundry Group, Rho, IOSG Ventures, Robot Ventures, Fenbushi Capital, HackVC, Industry Ventures, and others, bringing total funding to date to $34.0 million. The funding will be used to drive Blocknative's leadership in the emerging block building market.

Key Points: 
  • The Ethereum Merge introduced block builders as a new category of economic actors that provide core Ethereum capabilities.
  • To dependably transport high-value blocks to validators, Blocknative launched its block relay service immediately after The Merge.
  • Spencer Bogart, General Partner at Blockchain Capital, said, "The Merge marks a new era for Ethereum and a massive opportunity for Blocknative.
  • Founded in 2018, Blocknative helps inform and power such forward-thinking projects as Lido, MetaMask, imToken, Curve, Balancer, Ethereum Foundation, Polygon Foundation, and hundreds of others.

Boardable secures $2.6M in its most recent round led by Base10 Partners and hires Jon Schwander as CFO

Retrieved on: 
Wednesday, November 9, 2022
Organization, Transport, Historically black colleges and universities, Real economy, FTX, View, Communication, Highlander: The Series (season 1), Health, KeepTruckin, Multimedia, CEO, Management, University, Nubank

"Boardable is well-positioned to lead the next generation of efficient board management to mission-driven organizations," said Jeff Middlesworth, CEO of Boardable.

Key Points: 
  • "Boardable is well-positioned to lead the next generation of efficient board management to mission-driven organizations," said Jeff Middlesworth, CEO of Boardable.
  • "This additional investment will fund product innovation and accelerate growth in markets that need board management tools the most."
  • In addition to the round of funding, Boardable is also announcing the hiring of Jon Schwander as their Chief Financial Officer.
  • Jon joins Boardable with an extensive background in the finance and software industries and is an active leader in nonprofit organizations.

NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million

Retrieved on: 
Friday, September 9, 2022
Cosmetics, Retail, Health, Consumer, Women, Pharmaceutical, Optical, NovaBay Pharmaceuticals, Preferred stock, Capital Purchase Program, Security (finance), Private placement, Exercise, Reverse stock split, NYSE, Securities Act of 1933, Ladenburg Thalmann, Exchange, Participation, Highlander: The Series (season 1), Solution, Sale, Letter, SEC, Certificate, Company, Originality, NYSE American, Marketing, Private Securities Litigation Reform Act, Securities and Exchange Commission (Nigeria), Patient, Warrant, Series

The Company expects to receive gross proceeds from the private placement of approximately $3.25 million.

Key Points: 
  • The Company expects to receive gross proceeds from the private placement of approximately $3.25 million.
  • NovaBay intends to use the net proceeds received from the offering for working capital and general corporate purposes.
  • Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the private placement and as warrant solicitation agent for the warrant reprice transactions.
  • NovaBay Pharmaceuticals, Inc. creates science-based, problem-solving, accessible solutions for improved well-being through its two brands, Avenova and DERMAdoctor.

Overstock Reports Voting Results of Annual Meeting of Stockholders

Retrieved on: 
Thursday, May 12, 2022
FICC, Digital, Company, Certificate, Conversion, Highlander: The Series (season 1), Overstock, U.S. Securities and Exchange Commission, KPMG LLP, Common stock, Director, NASDAQ, Overstock.com, KPMG, Securities Act of 1933, Securities Exchange Act of 1934, SALT, Depository Trust & Clearing Corporation, Board, Name, OSTK, DTCC, SEC, OTCQX, TZero, Annual report, GLOBE, Management, Security (finance), State, Series

SALT LAKE CITY, May 12, 2022 (GLOBE NEWSWIRE) -- Overstock.com, Inc. (NASDAQ:OSTK), a leading home furnishings e-commerce retailer, today announced voting results of the shareholder proposals considered at its annual meeting of stockholders held on Thursday, May 12, 2022. Shareholders voted in favor of re-electing Barbara H. Messing, Robert J. Shapiro, and Joseph J. Tabacco to the Board of Directors, and converting the Series A-1 and Series B preferred stock into common stock. Shareholders also ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year 2022.

Key Points: 
  • SALT LAKE CITY, May 12, 2022 (GLOBE NEWSWIRE) -- Overstock.com, Inc. (NASDAQ:OSTK), a leading home furnishings e-commerce retailer, today announced voting results of the shareholder proposals considered at its annual meeting of stockholders held on Thursday, May 12, 2022.
  • Shareholders also ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year 2022.
  • Im pleased that our shareholders overwhelmingly voted to re-elect Barb, Rob, and Joe, said Overstock CEO Jonathan Johnson.
  • The voting results announced today are considered preliminary until final results are tabulated and certified by the independent Inspector of Elections.

Osmol Therapeutics Announces Closing of Series A-1 Funding to Advance the Clinical Development of the First Therapy to Prevent Chemotherapy-Induced Neuropathy

Retrieved on: 
Tuesday, April 12, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Investigational New Drug, IND, Highlander: The Series (season 1), Government budget balance, Research, Toxicity, Yale University, Central nervous system, Food and Drug Administration, Chemotherapy-induced peripheral neuropathy, Patient, Series, CIPN, Trial of the century, Breast cancer, NCS1, Â, FDA, Quality of life, Therapy, Cancer, Pharmaceutical industry, Osmotic concentration

Osmols lead drug candidate, OSM-0205, is based on Dr. Barbara Ehrlichs research in neuronal calcium sensor-1 (NCS1) and was in-licensed from Yale University.

Key Points: 
  • Osmols lead drug candidate, OSM-0205, is based on Dr. Barbara Ehrlichs research in neuronal calcium sensor-1 (NCS1) and was in-licensed from Yale University.
  • OSM-0205 is designed to prevent the off-target calcium surge caused by taxanes and potentially other chemotherapy treatments associated with peripheral nerve damage.
  • Osmol Therapeutics is well-positioned to be a first mover in the treatment of CIPN.
  • Osmol Therapeutics is a privately held biopharma company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN) based on the ground-breaking work of Dr. Barbara Ehrlich.

Entefy closes latest funding round and adds Paul Ross, former CFO of The Trade Desk, to its Board of Directors

Retrieved on: 
Tuesday, February 1, 2022
Growth, CEO, PWC, Intellectual property, PALO, Automation, Organization, University, Highlander: The Series (season 1), IP, CFO, AI, The Trade Desk, Technology, Certified Public Accountant, Board of directors, Board, CPA, Workforce, University of California, Certification, University of Southern California, Consumer, IPO, MBA, Management

PALO ALTO, Calif., Feb. 1, 2022 /PRNewswire/ -- Entefy Inc. announced today the appointment of Paul Ross to its Board of Directors.

Key Points: 
  • PALO ALTO, Calif., Feb. 1, 2022 /PRNewswire/ -- Entefy Inc. announced today the appointment of Paul Ross to its Board of Directors.
  • As a multi-time public company CFO, Ross brings to Entefy a wealth of finance and scale leadership experience.
  • Entefy hits key growth targets including its AI technology footprint, company valuation, customer orders, and IP.
  • Entefy Chairman and CEO, Alston Ghafourifar, said, "I'm delighted to welcome Paul to Entefy's Board of Directors.